Skip to main content
Evidence Snapshot

Leishmania donovani

CHEMBL367 ORGANISM Leishmania donovani
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:57:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL367
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leishmania donovani as ChEMBL target CHEMBL367. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leishmania donovani
ORGANISM · Leishmania donovani
As of 2026-09-13
ChEMBL target ID
CHEMBL367
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Leishmania donovani matters

As of 2026-09-13

Leishmania donovani is reviewed as Leishmania donovani; the current evidence base includes 56 approved drugs, 78069 compounds, and 2138 assays, with lead potency reaching pChEMBL 9.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 56 approved drugs, 78069 compounds, and 2138 assays for this target. The dominant activity type is IC50. CHEMBL218650 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL218650 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
56 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Leishmania donovani matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

78069
Total Compounds
2138
Total Assays
56
Approved Drugs
IC50: 11928.0, KI: 9.0, EC50: 1101.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL218650
 9.9 IC50 Approved
No preferred name
CHEMBL125
 9.6 IC50 Approved
No preferred name
CHEMBL4763675
 9.0 IC50 —
No preferred name
CHEMBL231385
 8.8 IC50 —
No preferred name
CHEMBL55
 8.7 IC50 Approved

Approved Drugs

Structure Compound First Approval
NIFURTIMOX
CHEMBL290960
 2020
DELAMANID
CHEMBL218650
 2014
MILTEFOSINE
CHEMBL125
 2014
CLOFAZIMINE
CHEMBL1292
 1986
PENTAMIDINE
CHEMBL55
 1984
NICLOSAMIDE
CHEMBL1448
 1982
KETOCONAZOLE
CHEMBL157101
 1981
PAROMOMYCIN
CHEMBL370143
 1969
AMPHOTERICIN B
CHEMBL267345
 1964
FURAZOLIDONE
CHEMBL1103
 1958
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:57:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL367